Answers are grounded in this paper and cite their sources.
This study uses Medicaid drug utilization data to describe reimbursement and market share of long-acting insulins before and after approval of new insulin products and to estimate savings associated with a “biosimilar” for insulin glargine approved in 2015.
No takes yet. Share an insight, caveat, or question.
Hernandez et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: